Elliot Assistant Professor of Biology Dr. Kristian M. Hargadon ’01 recently published an editorial article entitled “The Role of Tumor/Dendritic Cell Interactions in the Regulation of Anti-tumor Immunity: The Good, The Bad, and The Ugly” for a Research Topic in the peer-reviewed journal Frontiers in Immunology.  Following his publication of an article in Cellular Immunology on melanoma-associated suppression of dendritic cells, Dr. Hargadon was approached by Frontiers in Immunology and asked to serve as Guest Editor for a special issue on tumor/dendritic cell interactions.  This special issue includes 17 articles from leading tumor immunologists around the world who are researching the interactions between tumors and dendritic cells, a cell type of the immune system that regulates anti-tumor immune responses.  In addition to his Editorial article, Dr. Hargadon published his own review article on tumor-altered dendritic cell function in 2013 as part of this Research Topic.  Other contributors to this special issue include Rolf Zinkernagel (the 1996 recipient of the Nobel Prize in Physiology or Medicine) and investigators from the Mount Sinai School of Medicine, Harvard Medical School, the University of Arkansas for Medical Sciences, the University of Michigan Comprehensive Cancer Center, the University of Virginia, and oncology/hematology/tumor immunology research centers in Switzerland, France, the Netherlands, Germany, Belgium, and Italy.  Frontiers in Immunology is the official journal of the International Union for Immunological Societies, and this special issue is sure to bring focused attention both to recent advances in our understanding of tumor/dendritic cell interactions and to questions that remain to be answered in the field as these and other investigators aim to improve the quality of dendritic cell-mediated immune responses in cancer patients.

The Editorial for this Research Topic may be accessed at: http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00178/full